LAVA Therapeutics NV (LVTX) - Total Assets
Based on the latest financial reports, LAVA Therapeutics NV (LVTX) holds total assets worth $51.91 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LAVA Therapeutics NV - Total Assets Trend (2019–2024)
This chart illustrates how LAVA Therapeutics NV's total assets have evolved over time, based on quarterly financial data. Also see market value of LAVA Therapeutics NV for the company's overall valuation and market capitalisation.
LAVA Therapeutics NV - Asset Composition Analysis
Current Asset Composition (December 2024)
LAVA Therapeutics NV's total assets of $51.91 Million consist of 98.1% current assets and 1.9% non-current assets. Review LVTX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how LAVA Therapeutics NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LAVA Therapeutics NV stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LAVA Therapeutics NV's current assets represent 98.1% of total assets in 2024, an increase from 86.6% in 2019.
- Cash Position: Cash and equivalents constituted 43.3% of total assets in 2024, down from 83.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
LAVA Therapeutics NV Competitors by Total Assets
Key competitors of LAVA Therapeutics NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
LAVA Therapeutics NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.27 | 5.36 | 2.48 |
| Quick Ratio | 12.27 | 5.36 | 2.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $47.67 Million | $66.34 Million | $10.89 Million |
LAVA Therapeutics NV - Advanced Valuation Insights
This section examines the relationship between LAVA Therapeutics NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.61 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -20.5% |
| Total Assets | $80.83 Million |
| Market Capitalization | $45.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values LAVA Therapeutics NV's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LAVA Therapeutics NV's assets decreased by 20.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LAVA Therapeutics NV (2019–2024)
The table below shows the annual total assets of LAVA Therapeutics NV from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $80.83 Million | -20.53% |
| 2023-12-31 | $101.71 Million | -29.08% |
| 2022-12-31 | $143.43 Million | +3.00% |
| 2021-12-31 | $139.25 Million | +579.72% |
| 2020-12-31 | $20.49 Million | +132.87% |
| 2019-12-31 | $8.80 Million | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more